CL2017002686A1 - Métodos para tratar o prevenir dolor de cabeza por migraña - Google Patents

Métodos para tratar o prevenir dolor de cabeza por migraña

Info

Publication number
CL2017002686A1
CL2017002686A1 CL2017002686A CL2017002686A CL2017002686A1 CL 2017002686 A1 CL2017002686 A1 CL 2017002686A1 CL 2017002686 A CL2017002686 A CL 2017002686A CL 2017002686 A CL2017002686 A CL 2017002686A CL 2017002686 A1 CL2017002686 A1 CL 2017002686A1
Authority
CL
Chile
Prior art keywords
methods
migraine headache
treat
cgrp receptor
prevent migraine
Prior art date
Application number
CL2017002686A
Other languages
English (en)
Inventor
Hong Sun
Eduardo Dunayevich
Robert A Lenz
Gabriel Vargas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53969433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002686(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017002686A1 publication Critical patent/CL2017002686A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)

Abstract

<p>La presente invención se refiere a métodos de profilaxis de migraña utilizando anticuerpos anti-receptor CGRP o fragmentos de unión. En particular, se describen los métodos para prevenir o reducir la ocurrencia de dolor de cabeza por migraña en un paciente en necesidad del mismo comprende administrar al paciente un receptor anti-CGRP o fragmento de unión de acuerdo con los regímenes de dosificación específicos. También se describen composiciones farmacéuticas y dispositivos de administración que comprenden anticuerpos anti-receptor CGRP o fragmentos de unión para el uso en los métodos.</p>
CL2017002686A 2015-04-24 2017-10-23 Métodos para tratar o prevenir dolor de cabeza por migraña CL2017002686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
CL2017002686A1 true CL2017002686A1 (es) 2018-05-11

Family

ID=53969433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002686A CL2017002686A1 (es) 2015-04-24 2017-10-23 Métodos para tratar o prevenir dolor de cabeza por migraña

Country Status (31)

Country Link
US (3) US10259877B2 (es)
EP (2) EP3653225B1 (es)
JP (5) JP6392471B2 (es)
KR (1) KR102464415B1 (es)
CN (2) CN113908268B (es)
AU (2) AU2015392215B2 (es)
BR (1) BR112017022772A2 (es)
CA (1) CA2984254C (es)
CL (1) CL2017002686A1 (es)
CY (1) CY1123211T1 (es)
DK (2) DK3285803T3 (es)
ES (2) ES3005228T3 (es)
FI (1) FI3653225T3 (es)
HR (2) HRP20200056T1 (es)
HU (2) HUE048528T2 (es)
IL (2) IL291153B2 (es)
JO (2) JO3559B1 (es)
LT (2) LT3653225T (es)
MA (2) MA41932B1 (es)
MX (2) MX387530B (es)
PH (1) PH12017501934A1 (es)
PL (2) PL3653225T3 (es)
PT (2) PT3285803T (es)
RS (2) RS66352B1 (es)
RU (1) RU2707745C2 (es)
SG (2) SG10202004282RA (es)
SI (2) SI3285803T1 (es)
SM (1) SMT202000067T1 (es)
TW (2) TWI728953B (es)
WO (1) WO2016171742A1 (es)
ZA (1) ZA201707179B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519224B2 (en) 2014-03-21 2019-12-31 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US11028161B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
JP7195262B2 (ja) 2017-03-02 2022-12-23 ベス イスラエル デアコネス メディカル センター インコーポレイティッド カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法
WO2019055399A1 (en) * 2017-09-12 2019-03-21 Igc Bio, Inc. ANTI-VEGF ANTIBODIES
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
TW202019459A (zh) 2018-07-05 2020-06-01 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
GEAP202515803A (en) 2019-05-02 2025-06-10 H Lundbeck As Treatment of headache using anti-cgrp antibodies
WO2021005497A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
WO2021005494A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders
US20210130445A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders
US11607395B2 (en) * 2019-12-18 2023-03-21 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
CA3181130A1 (en) 2020-06-03 2021-12-09 William J. Binder Zonal and targeted methods and uses for treating a migraine disorder
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
KR102775899B1 (ko) 2023-12-19 2025-02-28 한림대학교 산학협력단 삽화성 편두통 및 만성 편두통 진단을 위한 정보제공 방법, 장치 및 컴퓨터 프로그램
US20260217773A1 (en) * 2024-09-17 2026-07-30 Neurocarrus Inc. Compositions and methods for treating and preventing headaches

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
MXPA05001649A (es) 2002-08-12 2005-05-27 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
SI3045182T1 (en) * 2005-11-14 2018-08-31 Teva Pharmaceuticals International Gmbh An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates
EP1951042B1 (en) 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam tricyclic cgrp receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
WO2007133491A1 (en) 2006-05-09 2007-11-22 Merck & Co., Inc. Substituted spirocyclic cgrp receptor antagonists
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
US8372859B2 (en) 2007-04-11 2013-02-12 Merck, Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
WO2008130524A1 (en) 2007-04-16 2008-10-30 Merck & Co., Inc. Aryl heterocyclic cgrp receptor antagonists
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
MX2010009724A (es) 2008-03-04 2010-09-28 Pfizer Ltd Procedimientos de tratamiento del dolor inflamatorio-.
US8377955B2 (en) 2008-06-12 2013-02-19 Merck, Sharp & Dohme, Corp. Branched 3- and 6-substituted quinolines as CGRP receptors antagonists
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
AU2009293471A1 (en) 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone CGRP receptor antagonists
JP2012504625A (ja) 2008-10-03 2012-02-23 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニスト
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
EA033109B1 (ru) * 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
CN108014334B (zh) * 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
PT3495392T (pt) 2011-05-20 2021-09-22 H Lundbeck As Composições anti-cgrp e a sua utilização
KR102215405B1 (ko) 2013-03-15 2021-02-10 암젠 인크 인간 pac1 항체
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UY36302A (es) * 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519224B2 (en) 2014-03-21 2019-12-31 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US11555064B2 (en) 2014-03-21 2023-01-17 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US11028161B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US11028160B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US12139528B2 (en) 2016-09-23 2024-11-12 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Also Published As

Publication number Publication date
HUE048528T2 (hu) 2020-07-28
AU2015392215A1 (en) 2017-11-09
PT3285803T (pt) 2020-02-18
IL291153B2 (en) 2023-06-01
JP2024138374A (ja) 2024-10-08
IL291153A (en) 2022-05-01
EP3653225A1 (en) 2020-05-20
SMT202000067T1 (it) 2020-03-13
ZA201707179B (en) 2020-01-29
US11466090B2 (en) 2022-10-11
WO2016171742A1 (en) 2016-10-27
CN113908268B (zh) 2025-06-10
EP3285803B1 (en) 2019-12-18
DK3285803T3 (da) 2020-02-17
SI3653225T1 (sl) 2025-02-28
AU2015392215B2 (en) 2022-04-07
SG10202004282RA (en) 2020-06-29
JP7544766B2 (ja) 2024-09-03
CN108156814A (zh) 2018-06-12
RS66352B1 (sr) 2025-01-31
LT3653225T (lt) 2025-01-10
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
TW201637667A (zh) 2016-11-01
TW202130369A (zh) 2021-08-16
MX387530B (es) 2025-03-18
HUE069646T2 (hu) 2025-03-28
JP6707590B2 (ja) 2020-06-10
ES2771925T3 (es) 2020-07-07
JP2020143115A (ja) 2020-09-10
PL3285803T3 (pl) 2020-06-01
EP3653225B1 (en) 2024-10-02
IL255114B (en) 2022-04-01
IL255114A0 (en) 2017-12-31
US20230020514A1 (en) 2023-01-19
JOP20200116B1 (ar) 2024-12-22
FI3653225T3 (fi) 2024-12-19
PH12017501934A1 (en) 2018-03-19
CN108156814B (zh) 2021-07-09
LT3285803T (lt) 2020-02-10
CY1123211T1 (el) 2021-12-31
MA41932B1 (fr) 2020-04-30
BR112017022772A2 (pt) 2018-07-31
RU2017140789A3 (es) 2019-05-24
CA2984254A1 (en) 2016-10-27
JO3559B1 (ar) 2020-07-05
CN113908268A (zh) 2022-01-11
AU2022204866A1 (en) 2022-08-18
SI3285803T1 (sl) 2020-02-28
PT3653225T (pt) 2024-12-30
AU2022204866B9 (en) 2025-08-14
JOP20200116A1 (ar) 2017-06-16
TWI728953B (zh) 2021-06-01
TWI799849B (zh) 2023-04-21
HRP20241717T1 (hr) 2025-02-14
MX2021013327A (es) 2021-11-17
RS59912B1 (sr) 2020-03-31
HK1250914A1 (en) 2019-01-18
EP3285803A1 (en) 2018-02-28
ES3005228T3 (en) 2025-03-14
MA51815A (fr) 2020-12-23
US20160311913A1 (en) 2016-10-27
RU2707745C2 (ru) 2019-11-29
JP6392471B2 (ja) 2018-09-19
US20190256607A1 (en) 2019-08-22
PL3653225T3 (pl) 2025-03-10
KR102464415B1 (ko) 2022-11-04
JP2019001800A (ja) 2019-01-10
DK3653225T3 (da) 2025-01-02
HRP20200056T1 (hr) 2020-04-03
CA2984254C (en) 2019-09-24
SG11201708607WA (en) 2017-11-29
MX2017013627A (es) 2018-07-06
JP2018513871A (ja) 2018-05-31
KR20180002711A (ko) 2018-01-08
JP2022126724A (ja) 2022-08-30

Similar Documents

Publication Publication Date Title
MX2021013327A (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2019000760A1 (es) Tratamiento de migraña refractaria
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12017501774A1 (en) Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX378344B (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
EA202190966A1 (ru) Пролекарства антагонистов cgrp
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
MX2022006812A (es) Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
BR112019011461A2 (pt) terapia celular à base de nk melhorada
MX2022001411A (es) Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.
BR112017002729A2 (pt) terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo